AbbVie Inc. $ABBV Stock Position Boosted by Investment Partners LTD.

Posted by George Bondi on Nov 1st, 2026

Investment Partners LTD. raised its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 82.2% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 10,925 shares of the company’s stock after acquiring an additional 4,928 shares during the quarter. Investment Partners LTD.’s holdings in AbbVie were worth $2,858,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Burk Holdings LLC acquired a new stake in AbbVie in the second quarter valued at $30,000. Marquette Asset Management LLC lifted its holdings in AbbVie by 52.2% during the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock worth $35,000 after buying an additional 48 shares during the period. Principia Wealth Advisory LLC lifted its holdings in AbbVie by 38.9% during the 2nd quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock worth $40,000 after buying an additional 44 shares during the period. IMG Wealth Management Inc. grew its position in shares of AbbVie by 3,060.0% in the 2nd quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock valued at $40,000 after buying an additional 153 shares during the last quarter. Finally, Tacita Capital Inc bought a new stake in shares of AbbVie in the 2nd quarter valued at about $42,000. Institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance

Shares of NYSE:ABBV opened at $294.80 on Friday. The company has a market capitalization of $520.85 billion, a price-to-earnings ratio of 50.74, a P/E/G ratio of 1.35 and a beta of 0.24. The business’s 50-day moving average is $269.35 and its 200-day moving average is $237.23. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $298.74.

AbbVie (NYSE:ABBV – Get Free Report) last announced its earnings results on Friday, October 30th. The company reported $3.82 EPS for the quarter, beating the consensus estimate of $3.73 by $0.09. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The company had revenue of $17.40 billion for the quarter, compared to analyst estimates of $17.32 billion. During the same quarter in the prior year, the company earned $1.86 EPS. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. Analysts anticipate that AbbVie Inc. will post 13.92 EPS for the current year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date is Thursday, October 15th. AbbVie’s dividend payout ratio is presently 195.48%.

Analysts Set New Price Targets

ABBV has been the subject of several recent research reports. Scotiabank increased their price target on AbbVie from $280.00 to $320.00 and gave the company an “outperform” rating in a research note on Tuesday, October 6th. Guggenheim reiterated a “buy” rating and issued a $288.00 target price on shares of AbbVie in a report on Friday, October 9th. Argus increased their target price on shares of AbbVie from $250.00 to $270.00 in a research report on Tuesday, August 4th. The Goldman Sachs Group raised their price target on shares of AbbVie from $258.00 to $294.00 and gave the stock a “neutral” rating in a report on Friday, October 23rd. Finally, BNP Paribas Exane boosted their price target on shares of AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $279.86.

Get Our Latest Research Report on ABBV

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: Q3 results beat expectations. Adjusted earnings per share were $3.82 versus the $3.73 analyst consensus, while revenue rose 10.3% year over year to $17.404 billion, ahead of the $17.32 billion estimate. Adjusted EPS more than doubled from the prior-year quarter. AbbVie Reports Third-Quarter 2026 Financial Results
Positive Sentiment: Immunology and neuroscience provided strong momentum. Skyrizi generated $5.776 billion in revenue and Rinvoq produced $2.706 billion, helping immunology revenue increase 16.3%. Neuroscience revenue climbed 19.4%, led by Vraylar, therapeutic Botox, Ubrelvy and Qulipta. AbbVie Lifts 2026 Outlook as Immunology, Neuroscience Quarterly Sales Beat Views
Positive Sentiment: Management raised guidance and its dividend. AbbVie increased its 2026 adjusted EPS outlook to $13.95–$13.99 from $13.76–$13.96, despite including $0.69 per share of year-to-date acquired in-process research and development and milestone expenses. The company also announced a 5.2% dividend increase beginning with the February 2027 payment. AbbVie Raises FY26 Adjusted EPS Outlook and Boosts Dividend
Positive Sentiment: Pipeline expansion supports longer-term confidence. AbbVie completed its acquisition of Apogee Therapeutics, strengthening its immunology pipeline, while Qulipta also outperformed topiramate in a Phase 3 migraine-prevention study. AbbVie QULIPTA Phase 3 Migraine Prevention Trial
Negative Sentiment: Investors remain focused on valuation and concentration risks. Humira revenue fell 31.2% to $683 million, while aesthetics revenue declined 1.4%. After a substantial multiyear rally and trading near its 52-week high, analysts question whether additional valuation expansion is justified and how effectively AbbVie can sustain growth beyond Skyrizi and Rinvoq. Skyrizi and Rinvoq Dominate AbbVie Q3

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.06% of the stock is currently owned by company insiders.

AbbVie Company Profile

(Free Report)

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.